Tobacco use in first-episode psychosis, a multinational EU-GEI study.

Age of psychosis onset heavy use schizophrenia smoking substance use tobacco

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
Nov 2023
Historique:
pubmed: 15 5 2023
medline: 15 5 2023
entrez: 15 5 2023
Statut: ppublish

Résumé

Tobacco is a highly prevalent substance of abuse in patients with psychosis. Previous studies have reported an association between tobacco use and schizophrenia. The aim of this study was to analyze the relationship between tobacco use and first-episode psychosis (FEP), age at onset of psychosis, and specific diagnosis of psychosis. The sample consisted of 1105 FEP patients and 1355 controls from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We assessed substance use with the Tobacco and Alcohol Questionnaire and performed a series of regression analyses using case-control status, age of onset of psychosis, and diagnosis as outcomes and tobacco use and frequency of tobacco use as predictors. Analyses were adjusted for sociodemographic characteristics, alcohol, and cannabis use. After controlling for cannabis use, FEP patients were 2.6 times more likely to use tobacco [ Tobacco and heavy-tobacco use are associated with increased odds of FEP. These findings further support the relevance of tobacco prevention in young populations.

Sections du résumé

BACKGROUND BACKGROUND
Tobacco is a highly prevalent substance of abuse in patients with psychosis. Previous studies have reported an association between tobacco use and schizophrenia. The aim of this study was to analyze the relationship between tobacco use and first-episode psychosis (FEP), age at onset of psychosis, and specific diagnosis of psychosis.
METHODS METHODS
The sample consisted of 1105 FEP patients and 1355 controls from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We assessed substance use with the Tobacco and Alcohol Questionnaire and performed a series of regression analyses using case-control status, age of onset of psychosis, and diagnosis as outcomes and tobacco use and frequency of tobacco use as predictors. Analyses were adjusted for sociodemographic characteristics, alcohol, and cannabis use.
RESULTS RESULTS
After controlling for cannabis use, FEP patients were 2.6 times more likely to use tobacco [
CONCLUSIONS CONCLUSIONS
Tobacco and heavy-tobacco use are associated with increased odds of FEP. These findings further support the relevance of tobacco prevention in young populations.

Identifiants

DOI: 10.1017/S0033291723000806 PMID: 37185055
pubmed: 37185055
doi: 10.1017/S0033291723000806
pii: S0033291723000806
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7265-7276

Subventions

Organisme : Seventh Framework Programme
ID : HEALTH-2013-2.2.1-2-603196
Organisme : Brain and Behavior Research Foundation
ID : 24628
Organisme : Instituto de Salud Carlos III
ID : PI21/00701
Organisme : Comunidad de Madrid
ID : B2017/BMD-3740 AGES-CM-2
Organisme : Spanish National Plan for Scientific and Technical Research and Innovation
ID : RYC-2017-23144

Auteurs

T Sánchez-Gutiérrez (T)

Faculty of Health Science, Universidad Internacional de la Rioja (UNIR), Logroño, Spain.
ORCID: 0000-0003-3124-4975

E Rodríguez-Toscano (E)

Grupo de investigación en Psiquiatría, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Department of Experimental Psychology, Cognitive Processes and Speech Therapy at the Complutense University of Madrid, Madrid, Spain.

L Roldán (L)

Faculty of Psychology, Universidad Complutense de Madrid, Madrid, Spain.

L Ferraro (L)

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), Psychiatry Section, University of Palermo, Palermo, Italy.

M Parellada (M)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.

A Calvo (A)

Faculty of Psychology, Universidad Complutense de Madrid, Madrid, Spain.

G López (G)

Faculty of Health Science, Universidad Internacional de la Rioja (UNIR), Logroño, Spain.

M Rapado-Castro (M)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.
Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, 161 Barry Street, Carlton South, Victoria 3053, Australia.

D La Barbera (D)

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), Psychiatry Section, University of Palermo, Palermo, Italy.

C La Cascia (C)

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), Psychiatry Section, University of Palermo, Palermo, Italy.

G Tripoli (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), Psychiatry Section, University of Palermo, Palermo, Italy.

M Di Forti (M)

Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Mental Health Trust, London, UK.

R M Murray (RM)

Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK.

D Quattrone (D)

Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK.

C Morgan (C)

ESRC Centre for Society and Mental Health, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

J van Os (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands.

P García-Portilla (P)

Department of Medicine-Psychiatry, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain.

S Al-Halabí (S)

Department of Psychology, University of Oviedo, Oviedo, Spain.

J Bobes (J)

Department of Medicine-Psychiatry, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain.

L de Haan (L)

Early Psychosis Department, Amsterdam UMC, University of Amsterdam, Academic Psychiatric Centre, Arkin, Amsterdam, The Netherlands.

M Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), CIBERSAM, ISCIII, Barcelona, Spain.

J L Santos (JL)

Department of Psychiatry, Servicio de Psiquiatría Hospital 'Virgen de la Luz', Cuenca, Spain.

J Sanjuán (J)

Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain.

M Arrojo (M)

Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

A Ferchiou (A)

Fondation FondaMental, Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
AP-HP, Hopitaux Universitaires 'H. Mondor', DMU IMPACT, F-94010 Creteil, France.

A Szoke (A)

Fondation FondaMental, Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
AP-HP, Hopitaux Universitaires 'H. Mondor', DMU IMPACT, F-94010 Creteil, France.

B P Rutten (BP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.

S Stilo (S)

Department of Mental Health and Addiction Services, ASP Crotone, Crotone, Italy.

G D'Andrea (G)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

I Tarricone (I)

Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

C M Díaz-Caneja (CM)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.

C Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.

Classifications MeSH